Hofseth BioCare and Tradichem agree new licensing deal
Norwegian biotech company HBC, a manufacturer of high-value ingredients, hopes the partnership will enable it to secure a smooth supply chain for its two main ingredients in both countries.
The products
According to HBC, it is “founded on the core value of sustainability and optimal use of natural resources” and has an overarching aim to minimises waste and use resources efficiently.
The business finds a new use for by-products from aquaculture which would otherwise go untouched.
It believes a growing number of customers care deeply about where the ingredients used in their goods come from. As a result, many consumer product businesses are asking their suppliers to verify traceability back to sustainable sources.
HBC aims to support human applications by supplying high value-added biomarine ingredients. Its natural marine collagenic bone powder, CalGo (collagenic hydroxyapatite calcium), which is a microcrystalline hydroxyapatite form of calcium, also contains phosphorus and collagen.
The combination of both collagen and calcium means it is well placed to help with joint health and cartilage function.
Published in the Journal of Nutrition and Food Science, research has found salmon bone calcium to be more effective than other forms of calcium, including calcium gluconate and calcium carbonate, in increasing femur dimension and mineral density in lab rats.
OmeGo is an all-natural, fresh salmon oil with a wide range of fatty acids. It supports cardiovascular function and the maintenance of healthy cholesterol. Recent research has also highlighted a unique lipopeptide compound in the product that targets allergic inflammation.
A collaborative approach
The licensing deal enables Tradichem - which is experienced in developing, marketing, distributing and manufacturing nutraceuticals and APIs in more than 50 countries globally - the opportunity to cover a total population of 54 million in the Spanish and Portuguese markets.
José Ángel Marañón, Executive Vice President of Tradichem, said: “This agreement is fully aligned with the company values of circular economy, full traceability and sustainability.
“Moreover, Calgo and Omega are two science-based ingredients also aligned with our tradition of high-value ingredients with strong consumer benefits in different areas as bone health, women health and cardiovascular and respiratory conditions.”
In December 2021, HBC successfully gained New Dietary Ingredient status from the US Food and Drug Administration for OmeGo and CalGo.
As reported last year by NutraIngredients-USA, HBC has been eyeing significant global growth for its three flagship ingredients, which also includes ProGo (bioactive peptides).
The products offer solutions for a variety of health endpoints, such as weight management, iron status, inflammation, heart health and bone and joint health.
